Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulators Lead asset, IFx-Hu2.0, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback